

## **Product datasheet for TR314510**

## **OriGene Technologies, Inc.**9620 Medical Center Drive, Ste 200

Rockville, MD 20850, US
Phone: +1-888-267-4436
https://www.origene.com
techsupport@origene.com
EU: info-de@origene.com
CN: techsupport@origene.cn

## PRRC2A Human shRNA Plasmid Kit (Locus ID 7916)

**Product data:** 

**Product Type:** shRNA Plasmids

**Product Name:** PRRC2A Human shRNA Plasmid Kit (Locus ID 7916)

**Locus ID:** 7916

Synonyms: BAT2; D6S51; D6S51E; G2

Vector: pRS (TR20003)

E. coli Selection: Ampicillin

Mammalian Cell Puromycin

Selection:

Format:

Retroviral plasmids

Components: PRRC2A - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID =

7916). 5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free.

**RefSeq:** NM 004638, NM 080686, NM 080686.1, NM 080686.2, NM 004638.1, NM 004638.2,

NM 004638.3, BC060668, BC060668.1, BC030127, BC032134, BC042295, BM555411,

NM 080686.3, NM 004638.4

UniProt ID: P48634

**Summary:** A cluster of genes, BAT1-BAT5, has been localized in the vicinity of the genes for TNF alpha

and TNF beta. These genes are all within the human major histocompatibility complex class III region. This gene has microsatellite repeats which are associated with the age-at-onset of insulin-dependent diabetes mellitus (IDDM) and possibly thought to be involved with the inflammatory process of pancreatic beta-cell destruction during the development of IDDM.

This gene is also a candidate gene for the development of rheumatoid arthritis. Two transcript variants encoding the same protein have been found for this gene. [provided by

RefSeq, Dec 2010]

**shRNA Design:** These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our custom shRNA service.







## Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).